<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018651</url>
  </required_header>
  <id_info>
    <org_study_id>FIU IRB 105978</org_study_id>
    <nct_id>NCT04018651</nct_id>
  </id_info>
  <brief_title>Optimizing PrEP Utilization Among Alcohol and Other Drug (AOD) Using Women of Color</brief_title>
  <official_title>Optimizing PrEP Utilization Among Alcohol and Other Drug (AOD) Using Women of Color</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida International University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Florida International University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nationally, the HIV case rate among black/ African American (AA) women is nearly 20 times&#xD;
      higher than in white women; for Hispanic/Latino women it is 4.5 times higher. Moreover,&#xD;
      according to findings in the HIV Prevention Trials Network (HPTN) Study 064 (The Women's HIV&#xD;
      SeroIncidence Study), HIV incidence among women who live in communities with high HIV&#xD;
      prevalence and poverty is about 6 times higher than for black/AA women. South Florida's new&#xD;
      HIV diagnoses are now triple the national average due to rates in Miami-Dade and Broward&#xD;
      counties in its AA, Latino and Haitian communities. Black women follow black men who have sex&#xD;
      with men (MSM) as the most crisis-ridden of the communities in South Florida, the state as a&#xD;
      whole, the South, and the U.S. Women overall have been at a disadvantage in the HIV epidemic&#xD;
      due to gender differences and norms that shape biological, social and economic vulnerability.&#xD;
      Racial and ethnic disparities magnify the risk. Co-factors such as alcohol and other drug&#xD;
      (AOD) use intersect and reinforce other comorbidities. Living in a high prevalence area&#xD;
      significantly hardens the risk and makes it tougher to overcome. Options to help women stay&#xD;
      HIV negative have been limited, and the absence of practical female-controlled prevention&#xD;
      strategies and relative dependence on cooperative use of the male condom continue to keep&#xD;
      women's HIV vulnerability high. This obstacle shifted several years ago with FDA approval and&#xD;
      Centers for Disease Control and Prevention's (CDC) endorsement of oral pre-exposure&#xD;
      prophylaxis (PrEP). However, women do not know about PrEP. Despite FDA approval in 2012,&#xD;
      followed by expansions in recommended use from the CDC and World Health Organization (WHO),&#xD;
      the majority of women in the U.S. are not aware of oral PrEP as an HIV prevention strategy&#xD;
      that applies to them. This study utilizes community-based participatory research (CBPR) to&#xD;
      develop an intervention program that will promote optimal PrEP utilization among women of&#xD;
      color in South Florida. The overall goal is to determine how best to target and improve PrEP&#xD;
      utilization among women of color with substantial risks for HIV, including alcohol use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A singular limitation in the fight against HIV has been the absence of practical&#xD;
      female-controlled prevention strategies and relative dependence on cooperative use of the&#xD;
      male condom. Since 2012, medication for pre-exposure prophylaxis or PrEP has been&#xD;
      FDA-approved in the U.S., with guidance for its use extended to all individuals at&#xD;
      substantial risk in 2014 by the CDC and in 2015 by the WHO. In June 2016, the American&#xD;
      Medical Association (AMA) instituted policies in concurrence, and in July 2016 an updated&#xD;
      National HIV/AIDS Strategy was released making PrEP one of the four pillars in the nation's&#xD;
      effort against HIV. To date, the largest uptake and implementation has been among the MSM&#xD;
      population, which still bears the primary burden of the epidemic in the U.S. However, women&#xD;
      continue to face a highly disproportionate risk and significant barriers to progress due to&#xD;
      gender and structural disparities and biological susceptibility. Many of these barriers&#xD;
      revolve around disparities that limit agency, most pointedly in negotiation of safe sex. Yet,&#xD;
      existing studies indicate that very few of the women at substantial risk in the U.S. have&#xD;
      awareness of PrEP, either from community sources or their doctors. Moreover, a recent&#xD;
      national survey showed that PrEP awareness is suboptimal among a majority of providers.&#xD;
      Clearly, PrEP as a viable female-controlled method is a long way from being a key part of the&#xD;
      country's HIV strategy, and will require a community-driven approach to address demand and&#xD;
      supply, uptake and accessibility, to shift the terms of women's agency in HIV prevention.&#xD;
      This need is greatest among women of color, particularly when the use of alcohol and other&#xD;
      drugs (AOD) severely compounds their risk.&#xD;
&#xD;
      This U34 utilizes community-based participatory research (CBPR) to build upon a Pre-Meeting&#xD;
      of Community Stakeholders from the greater Miami and Fort Lauderdale areas, to develop an&#xD;
      intervention program that will promote optimal PrEP utilization among women of color in South&#xD;
      Florida who engage in risky sex and alcohol use. What is most potent in a CBPR-based study,&#xD;
      is community participation in defining problems and intervention components, identifying&#xD;
      applicable theories and evidence-based interventions (EBIs), and interpreting data and&#xD;
      outcomes. The research team is currently conducting an exploratory pilot test in Miami-Dade&#xD;
      County in South Florida, which leads the state in new HIV infections, and has a large&#xD;
      multiethnic distribution of Black and Latino women in its population. Florida currently ranks&#xD;
      1st in HIV diagnoses among all states in the U.S. The overall goal is to determine how best&#xD;
      to target and improve PrEP utilization among women of color with substantial risks for HIV,&#xD;
      including alcohol use.&#xD;
&#xD;
      The investigator's Specific Aims are:&#xD;
&#xD;
      Aim 1: Identify perceived needs, priorities, barriers, and community strengths in the&#xD;
      implementation of HIV prevention programs, with the development of a PrEP continuum care&#xD;
      model, by conducting a summit to engage a diverse range of HIV- and HIV+ women of color,&#xD;
      health care providers and community stakeholders.&#xD;
&#xD;
      Aim 2: Produce a replicable implementation program, including manuals, materials, screening&#xD;
      and assessment instruments, and procedures, through the formation of a Community Advisory and&#xD;
      Advocacy Board (CAAB) from summit participants, who will participate in a 2-day orientation&#xD;
      training workshop and form working groups with research team members to formulate study&#xD;
      methods and the intervention model.&#xD;
&#xD;
      Aim 3: Conduct an exploratory pilot of the PrEP model, implemented by the CAAB, in Broward&#xD;
      and Miami-Dade for fidelity, feasibility, and acceptability, among 120 multi-ethnic women of&#xD;
      color in South Florida (primarily African American (AA), Latina, Haitian). PrEP uptake and&#xD;
      adherence and retention in care will be measured over a 6 month period. Results will inform a&#xD;
      future U01, including the design of target and comparison groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants receiving 3 Medication Appointments</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Participants who receive 3 refills of medication for PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Adherence to PrEP Medication</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage adherence based on Pill count of remaining prescription medication at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self reported PrEP Adherence</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage Adherence to daily PrEP medication via self report at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants reporting Adherence to HIV testing recommendation</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Participants Receiving HIV test at 3 months</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>HIV Prevention</condition>
  <arm_group>
    <arm_group_label>PrEP Master Adherence Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention consists of an introductory session and 4 individual sessions led by the PrEP Master, over an 8 week period. Between the sessions, the PrEP Master will conduct weekly check-in calls to participants to encourage adherence and assist with difficulties. During the weekly check-in, side effects and their impact will be assessed using assessment measures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PrEP Master Adherence Intervention</intervention_name>
    <description>The PrEP Master Adherence Intervention consists of 4 face to face individual education sessions and a series of telephone contacts to identify barriers and facilitators to optimal PrEP adherence over a six-month period. Each PrEP Master education session includes a review of an individualized plan to reduce risk, review of information about PrEP, and different discussion points. Key messages include:&#xD;
Importance of daily adherence;&#xD;
Three week delay for full effectiveness describing PrEP like taking the birth control pill;&#xD;
Condom use for other sexually transmitted infection (STI) prevention;&#xD;
Pregnancy prevention plans;&#xD;
Plans for follow up calls&#xD;
Referral to other treatment services if necessary</description>
    <arm_group_label>PrEP Master Adherence Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 + years of age;&#xD;
&#xD;
          -  born female;&#xD;
&#xD;
          -  Identifies as female;&#xD;
&#xD;
          -  Identifies as African American, Hispanic/Latina or Haitian (self or parent);&#xD;
&#xD;
          -  Able to provide informed consent;&#xD;
&#xD;
          -  HIV uninfected;&#xD;
&#xD;
          -  Sexual risk (previous STI, inconsistent condom use, transactional sex, HIV infected&#xD;
             partner);&#xD;
&#xD;
          -  History of alcohol or drug use in last 3 months;&#xD;
&#xD;
          -  No uncleared PrEP contraindications;&#xD;
&#xD;
          -  No psychosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 18 years of age&#xD;
&#xD;
          -  male gender assignment at birth&#xD;
&#xD;
          -  current male gender identity&#xD;
&#xD;
          -  does not identify as African American, Haitian or Hispanic/Latina (self or parent)&#xD;
&#xD;
          -  reports history of or current untreated psychosis&#xD;
&#xD;
          -  unable to provide informed consent&#xD;
&#xD;
          -  HIV infected&#xD;
&#xD;
          -  Refuses PrEP medication&#xD;
&#xD;
          -  Untreated medical contraindication for PrEP&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female gender identity</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessy G DÃ©vieux, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida International Univ.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Jean-Gilles, Ph.D.</last_name>
    <phone>3059194207</phone>
    <email>gillesm@fiu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Florida International University Biscayne Bay Campus</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33181</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Ichite, MPH</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Florida International University</investigator_affiliation>
    <investigator_full_name>jessy g devieux</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pre-Exposure Prophylaxis</keyword>
  <keyword>PrEP</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

